Combined with overall desirable pharmacological features of the scaffold (Figure 2), high chemical stability and low cytotoxicity (selectivity index CC50/EC50 ??? 16,500 [106]), this class is an example of a novel developmental lead that is tailored to the specific requirements for a measles therapeutic.Figure 2The structure of AS-136AConclusionsThe Measles Initiative launched in 2001 has made imp